{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"56","value":"27"},{"groupId":"OG001","lowerLimit":"21","upperLimit":"44","value":"29"},{"groupId":"OG002","lowerLimit":"18","upperLimit":"56","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Donor age","dispersionType":"Full Range","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"},{"description":"Total number of participants","id":"OG002","title":"Total"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Pre-HCT","title":"Donor Selection Characteristics: Donor Age","type":"SECONDARY","unitOfMeasure":"years"}